Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity

Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity

mTOR inhibition can promote or inhibit immune responses in a context dependent manner, but whether this will represent a net benefit or be contraindicated in the context of immunooncology therapies is less understood. Here, we report that the mTORC1/2 dual kinase inhibitor vistusertib (AZD2014) pote...

Full description

Bibliographic Details
Main Authors: Sophie Langdon, Adina Hughes, Molly A. Taylor, Elizabeth A. Kuczynski, Deanna A. Mele, Oona Delpuech, Laura Jarvis, Anna Staniszewska, Sabina Cosulich, Larissa S. Carnevalli, Charles Sinclair
Format: Article
Language:English
Published: Taylor & Francis Group 2018-08-01
Series:OncoImmunology
Subjects:
checkpoint blackade
inflammation and cancer
kinase inhibitor
t cell activation
mtorc 1/2
mtor
t-cells
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1458810

Internet

http://dx.doi.org/10.1080/2162402X.2018.1458810

Similar Items